Research programme: therapeutics for mood and brain disorders - Janssen/University of Toronto

Drug Profile

Research programme: therapeutics for mood and brain disorders - Janssen/University of Toronto

Latest Information Update: 15 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Inc; University of Toronto
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease; Mood disorders

Most Recent Events

  • 15 Sep 2014 Janssen and University of Toronto agree to co-develop therapeutics in Canada for Mood disorders and Alzheimer's disease
  • 08 Sep 2014 Early research in Alzheimer's disease in Canada (unspecified route)
  • 08 Sep 2014 Early research in Mood disorders in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top